Acacia Pharma Group plc Results Of Annual General Meeting
June 29 2021 - 12:00AM
UK Regulatory
TIDMACPH
Acacia Pharma Group plc: Results of Annual General Meeting
Cambridge, UK and Indianapolis, US -- 29 June 2021: Acacia
Pharma Group plc ("Acacia Pharma", the "Company") (EURONEXT: ACPH)
announces that all resolutions as set out in the Notice of Annual
General Meeting dated 25 May 2021 were duly passed by the required
majority at the Annual General Meeting ("AGM") held yesterday.
The results of the votes on the resolutions are shown in the
table below and will be posted on the Company's website at
www.acaciapharma.com in the Investors/Shareholder Meetings
section.
Votes Votes Votes
Resolution Votes for % against % total withheld
--------------------------------------- ------------ -------- ---------- ------ ------------ ----------
To receive the consolidated
financial statements
and the reports of the
Directors and the auditor
for the year ended 31
December 2020 51,451,342 100.00 0 0.00 51,451,342 0
--------------------------------------- ------------ -------- ---------- ------ ------------ ----------
To approve the Directors'
Remuneration Policy 51,451,342 100.00 0 0.00 51,451,342 0
--------------------------------------- ------------ -------- ---------- ------ ------------ ----------
To approve the Directors'
Remuneration Report 51,451,342 100.00 0 0.00 51,451,342 0
--------------------------------------- ------------ -------- ---------- ------ ------------ ----------
To re-elect Scott Byrd
as a Director of the
Company 51,451,342 100.00 0 0.00 51,451,342 0
--------------------------------------- ------------ -------- ---------- ------ ------------ ----------
To re-elect Michael
Bolinder as a Director
of the Company 51,451,342 100.00 0 0.00 51,451,342 0
--------------------------------------- ------------ -------- ---------- ------ ------------ ----------
To re-elect Edward Borkowski
as a Director of the
Company 51,451,342 100.00 0 0.00 51,451,342 0
--------------------------------------- ------------ -------- ---------- ------ ------------ ----------
To re-elect John Brown
as a Director of the
Company 51,451,342 100.00 0 0.00 51,451,342 0
--------------------------------------- ------------ -------- ---------- ------ ------------ ----------
To elect Alessandro
Della Chá who was
appointed as a Director
of the Company since
the last Annual General
Meeting, as a Director
of the Company 51,451,342 100.00 0 0.00 51,451,342 0
--------------------------------------- ------------ -------- ---------- ------ ------------ ----------
To re-appoint PricewaterhouseCoopers
LLP as auditor of the
Company 51,451,342 100.00 0 0.00 51,451,342 0
--------------------------------------- ------------ -------- ---------- ------ ------------ ----------
To authorise the Directors
of the Company to agree
the remuneration of
the Company's auditor 51,451,342 100.00 0 0.00 51,451,342 0
--------------------------------------- ------------ -------- ---------- ------ ------------ ----------
Allotment of Shares 51,451,342 100.00 0 0.00 51,451,342 0
--------------------------------------- ------------ -------- ---------- ------ ------------ ----------
To disapply pre-emption
rights 51,451,342 100.00 0 0.00 51,451,342 0
--------------------------------------- ------------ -------- ---------- ------ ------------ ----------
To resolve to amend
the Articles of Association 51,451,342 100.00 0 0.00 51,451,342 0
--------------------------------------- ------------ -------- ---------- ------ ------------ ----------
As at the close of business on 24 June 2021 (being the time at
which shareholders who wanted to attend and vote at the meeting
were required to have their details entered in the register of
members) there were 99,713,951 shares of 2p each in issue.
Contacts
Acacia Pharma Group plc International Media
Mike Bolinder, CEO Mark Swallow, Frazer Hall, David
Gary Gemignani, CFO Dible
+44 1223 919760 / +1 317 505 1280 MEDiSTRAVA Consulting
IR@acaciapharma.com +44 20 7638 9571
acaciapharma@medistrava.com
US Investors Media in Belgium and the Netherlands
LifeSci Advisors Chris Van Raemdonck
Irina Koffler +32 499 58 55 31
+1 917-734-7387 chrisvanraemdonck@telenet.be
ikoffler@lifesciadvisors.com
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on
the development and commercialization of new products aimed at
improving the care of patients undergoing significant treatments
such as surgery, other invasive procedures, or cancer chemotherapy.
The Company has identified important and commercially attractive
unmet needs in these areas that its product portfolio aims to
address.
Acacia Pharma's first product, BARHEMSYS(R) (amisulpride
injection) is available in the US for the management of
postoperative nausea & vomiting (PONV).
BYFAVO(TM) (remimazolam) for injection, a very rapid
onset/offset IV benzodiazepine sedative is approved and launched in
the US for use during invasive medical procedures in adults lasting
30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is
in-licensed from Paion UK Limited for the US market.
APD403 (intravenous and oral amisulpride), a selective dopamine
antagonist for chemotherapy induced nausea & vomiting (CINV)
has successfully completed one proof-of-concept and one Phase 2
dose-ranging study in patients receiving highly emetogenic
chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and
its R&D operations are centred in Cambridge, UK. The Company is
listed on the Euronext Brussels exchange under the ISIN code
GB00BYWF9Y76 and ticker symbol ACPH.
Acacia Pharma Group plc
The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH,
United Kingdom
Company number 9759376
www.acaciapharma.com
(END) Dow Jones Newswires
June 29, 2021 01:00 ET (05:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2023 to Apr 2024
